Nouscom Announces Promotion of Richard Davis to Chief Operating Officer
BASEL, Switzerland, May 23, 2022 /PRNewswire/ — Nouscom, a clinical-stage immuno-oncology company developing ready-to-use and personalized viral-vectored immunotherapies, today announced the promotion of Richard (Rick) Davis, PhD to Chief Operating Officer (COO) with immediate effect. Rick joined Nouscom in September 2020 as business manager.
“Rick has been instrumental in growing the company since joining in 2020, proactively using his extensive networks to build relationships with major players in the field, as a foundation for future value-creating partnerships and to maximize the potential of our proprietary viral vector vaccine. Platform.” said Marina Udier, General Manager. “Rick played a very influential role in establishing and managing the collaboration with Janssen Oncology, which led to recent IND clearance from the US FDA of the first licensed program from Nouscom’s proprietary platform, VAC -85135, a ready-to-use viral vector-based potential cancer. vaccine.”
“The promotion to COO is well deserved and I look forward to continuing to work with Rick, maximizing his strategic business and fundraising expertise, as we position the company for continued growth and success.”
Rick has over 20 years of experience in the life sciences industry with significant business development and investment expertise, focused on building strategic partnerships and growth strategies. Rick joined Nouscom from Johnson and Johnson Innovation where he was the Global Oncology Venture and Transaction Lead seeking opportunities ranging from startups to collaborations with biotech companies. Rick has also held other investment, finance and business development positions at Wellcome Trust, leading healthcare investments in private and public equity and venture capital funds.
Prior to Johnson & Johnson, Rick was CEO of Trino Therapeutics, a private European biotechnology company. Rick has served on the board of several biotech companies, working closely with management teams on strategy, financing and exits through M&A and IPOs. Rick started his career at Pharmagene in clinical development after earning a PhD in Pharmacology from the University of Leicester.
Nouscom is a clinical-stage immuno-oncology company developing next-generation, ready-to-use, personalized cancer vaccines. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vector vaccines based on multiple neoantigens with other immunomodulators.
Nouscom is currently advancing the clinical development of its wholly owned programs:
- NOUS-209 (lead), a ready-to-use cancer immunotherapy for the treatment of Microsatellite Unstable High (MSI-H) solid tumors that reported positive interim safety, immunogenicity and clinical data in SITC 2021 and AACR 2022 conferences; and
- US-PEV, a personalized vaccine for the treatment of advanced melanoma or lung cancer
Nouscom is led by an experienced management team with deep roots in the pharmaceutical and biotechnology industry and is a veteran in the field of viral vector vaccines.
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Roma, Italyis backed by international life science investors.
For more information about Nouscom, please visit the company’s website at nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/
Rick Davischief operating officer
E: [email protected]
T: +41 61 201 1835
Sylvie Berrebi, Eleanor Perkin
E: [email protected]
T: +44 (0) 203 928 6900